JP2009256374A5 - - Google Patents

Download PDF

Info

Publication number
JP2009256374A5
JP2009256374A5 JP2009181759A JP2009181759A JP2009256374A5 JP 2009256374 A5 JP2009256374 A5 JP 2009256374A5 JP 2009181759 A JP2009181759 A JP 2009181759A JP 2009181759 A JP2009181759 A JP 2009181759A JP 2009256374 A5 JP2009256374 A5 JP 2009256374A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
stem cells
nitric oxide
oxide donor
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009181759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009256374A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009256374A publication Critical patent/JP2009256374A/ja
Publication of JP2009256374A5 publication Critical patent/JP2009256374A5/ja
Pending legal-status Critical Current

Links

JP2009181759A 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー Pending JP2009256374A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003557275A Division JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー

Publications (2)

Publication Number Publication Date
JP2009256374A JP2009256374A (ja) 2009-11-05
JP2009256374A5 true JP2009256374A5 (enExample) 2010-09-16

Family

ID=23355218

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー
JP2009181759A Pending JP2009256374A (ja) 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー

Country Status (9)

Country Link
US (2) US20050143388A1 (enExample)
EP (1) EP1469852A4 (enExample)
JP (2) JP4545440B2 (enExample)
CN (1) CN1638775A (enExample)
AU (1) AU2003210447B2 (enExample)
CA (1) CA2471147C (enExample)
IL (1) IL162850A0 (enExample)
WO (1) WO2003056899A2 (enExample)
ZA (1) ZA200405507B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
EP1951237A2 (en) * 2005-11-14 2008-08-06 The Trustees of Columbia University in The City of New York Imaging correlates of neurogenesis with mri
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
JP2010527928A (ja) 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
WO2009059271A1 (en) * 2007-11-02 2009-05-07 University Of Miami Diagnosis and treatment of cardiac disorders
MY173949A (en) 2012-04-25 2020-02-28 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
CA2908482A1 (en) * 2013-03-01 2014-09-04 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
US20250041309A1 (en) * 2021-12-14 2025-02-06 Zhenao Jinyinhua Pharmaceutical Use of aildenafil or salt thereof in preparation of medicine for preventing or treating ischemic brain damage
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755685A4 (en) * 1994-04-15 2000-05-03 Meiji Seika Kaisha PHARMACEUTICAL COMPOSITION FOR TREATING LATE DYSKINESIA
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
ES2531592T3 (es) 1999-05-14 2015-03-17 Henry Ford Health System Trasplante de médula ósea para el tratamiento de la apoplejía
IL147112A0 (en) 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
EP2316531A1 (en) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training

Similar Documents

Publication Publication Date Title
JP2012255026A5 (enExample)
JP2010222367A5 (enExample)
JP2013518056A5 (enExample)
EP2364144A4 (en) PHARMACEUTICAL FORM FOR ADMINISTRATION THROUGH THE MOUTH
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
JP2012500090A5 (enExample)
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
HRP20240168T1 (hr) Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
JP2014532722A5 (enExample)
NZ593475A (en) Calcium salts for reducing exhalation of infectious bioaerosol particles
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
RU2014142025A (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
JP2012518646A5 (enExample)
JP2007238598A5 (enExample)
JP2013543518A5 (enExample)
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
JP2002537232A5 (enExample)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
JP2011516572A5 (enExample)
JP2006342148A5 (enExample)
RU2011137413A (ru) Применение кардиотрофина-1 для лечения метаболических заболеваний
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.